Login to Your Account



XIX International AIDS Conference

LIMCs Are Not Buying That Patents Critical for HIV Drugs

By Anette Breindl
Science Editor

Monday, July 30, 2012

WASHINGTON – HIV medications are somewhat unusual in that there is enough of a demand for them in the developed world to make developing such medications worth the biopharma industry's while. But the majority of the people who need them are not able to pay their asking price in the West – or rather, the national health systems of the low and middle-income countries (LIMCs) they call home are not able to afford the price tag.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription